TABLE 4.
Summary of the V peptide conjugate challenge experimenta
| Immunogen | ELISA titerb | MTD (days) ± SDc | No. of mice surviving/ total no.d |
|---|---|---|---|
| V peptide 1–30 plus KLH | 1,310,720 | 7.8 ± 1.3 | 4/9 |
| V peptide 101–120 plus KLH | 655,360 | 4.7 ± 0.9 | 0/9 |
| V peptide 116–136 plus KLH | 163,840 | 4.7 ± 1.1 | 0/10 |
| V peptide 168–197 plus KLH | 163,840 | 4.7 ± 0.9 | 0/10 |
| V peptide 277–296 plus KLH | 327,680 | 4.6 ± 0.5 | 0/10 |
| V peptide 287–306 plus KLH | 163,840 | 5.1 ± 0.7 | 0/10 |
| V protein in CFA | 1,310,720 | 9/9 | |
| Plague Vaccine USP | <640 | 21 ± 6.4 | 8/10 |
| KLH alone | <640 | 5.1 ± 0.9 | 0/10 |
a
Hsd:ND4 mice were immunized three times i.p. with either peptide, V protein, or Plague Vaccine USP.
b
Serum obtained from immunized animals was pooled and analyzed for the response to recombinant V antigen.
c
MTD ± SD, mean time to death ± standard deviation.
d
Mice were challenged s.c. with 100 LD50 of Y. pestis CO92 approximately 30 days after the last immunization.